Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective study
BMC Gastroenterol. 2023 Feb 2;23(1):31.
doi: 10.1186/s12876-022-02636-9.
1 CHU Rennes, University Rennes, 35000, Rennes, France.
2 CHU Lille, University of Lille, Lille, France.
3 CHU Nantes, Nantes, France.
4 CHU Saint-Etienne, Saint- Étienne, France.
5 Inserm U954 Deparment of Hepato-Gastroenterology, Department of Gastroenterology, Nancy University Hospital, Vandœuvre-Lès-Nancy, France.
6 CHU Caen, Caen, France.
7 Clinique Jules Vernes, Nantes, France.
8 CHU de Bordeaux, Hôpital Haut-Lévêque, Service d'Hépato-Gastroentérologie Et Oncologie Digestive, Université de Bordeaux, 33000, Bordeaux, France.
9 CHU Rennes, University Rennes, INSERM, CIC1414, Institute NUMECAN (Nutrition Metabolism and Cancer), 35000, Rennes, France.
10 Service d'Hépato-Gastroentérologie Et Oncologie Digestive, CHU Amiens Et PeriTox, UMR I0-I, Université de Picardie, Amiens, France.
11 CHU Rennes, University Rennes, INSERM, CIC1414, Institute NUMECAN (Nutrition Metabolism and Cancer), 35000, Rennes, France. guillaume.bouguen@chu-rennes.fr.
12 Service Des Maladies de L'Appareil Digestif, 2 Rue Henri Le Guillou, 35033, Rennes Cedex, France. guillaume.bouguen@chu-rennes.fr.